Otsuka to commercialise hereditary angioedema drug in Europe
Japanese company Otsuka Pharmaceutical will pay $65 million is to commercialise Ionis’ hereditary angioedema candidate in Europe.
List view / Grid view
Japanese company Otsuka Pharmaceutical will pay $65 million is to commercialise Ionis’ hereditary angioedema candidate in Europe.
Takeda has announced late-breaking Phase III trial data showing that Takhzyro® (lanadelumab) reduces hereditary angioedema (HAE) attacks by roughly 95 percent in children aged two to
In its latest meeting the CHMP recommended eight medications for approval, 17 medicines for indication extension and concluded reviews of two COVID-19 treatments.
Lanadelumab, a preventive treatment for hereditary angioedema, has been recommended as a cost-effective use of NHS resources.
Results of a clinical trial has led to the FDA approval of a monoclonal antibody drug called lanadelumab, to treat hereditary angioedema attacks...
11 August 2016 | By KalVista
This first clinical study will evaluate the key characteristics of safety, drug exposure and bioactivity (plasma kallikrein inhibition) achieved after oral dosing of KVD818. This clinical trial is being conducted in the UK with results of the study expected in spring 2017...
9 February 2016 | By Victoria White
Under the extended agreement, Cytobioteck will also exclusively distribute Ruconest in Argentina, Costa Rica, the Dominican Republic and Panama...
6 January 2016 | By Victoria White
Pharming has completed patient enrolment in the Phase 2 clinical study of Ruconest (recombinant C1 esterase Inhibitor, 50 IU/kg) for prophylaxis in patients with hereditary angioedema (HAE).
3 November 2015 | By Victoria White
Shire has announced that it is to acquire Dyax, a company focused on the development of plasma kallikrein inhibitors for the treatment of hereditary angioedema, for approximately $5.9 billion...
13 October 2015 | By Victoria White
Cinryze is being studied as an adjunct treatment to Donor Specific Antibodies (DSA) reduction therapy in kidney transplant patients with acute antibody mediated rejection...
8 October 2015 | By Victoria White
The exclusivity ensures that the FDA will not approve any applications for biosimilars of the drug before July 2026...